Quality assurance in human papillomavirus testing for primary cervical screening

Int J Gynecol Cancer. 2023 May 1;33(5):802-811. doi: 10.1136/ijgc-2022-004197.

Abstract

The recommendation for cervical screening is that it should be based on human papillomavirus (HPV) molecular testing. For all screening programs, attention to quality assurance is required to fully realize the benefits. Internationally recognized quality assurance recommendations for HPV-based screening are needed that are ideally applicable for a variety of settings, including in low- and middle-income countries. We summarize the main points of quality assurance for HPV screening, with a focus on the selection, implementation, and use of an HPV screening test, quality assurance systems (including internal quality control and external quality assessment), and staff competence. While we recognize that it might not be possible to fulfill all points in all settings, an awareness of the issues is essential.

Keywords: Cervical Cancer; Cervix Uteri.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cervix Uteri
  • Early Detection of Cancer
  • Female
  • Human Papillomavirus Viruses
  • Humans
  • Mass Screening
  • Papillomaviridae
  • Papillomavirus Infections*
  • Uterine Cervical Neoplasms* / diagnosis
  • Vaginal Smears